CD38 expression level and pattern of expression remains a reliable and robust marker of progressive disease in chronic lymphocytic leukemia

Amjad Hayat, David O'Brien, Paul O'Rourke, Siobhan McGuckin, Tony Fitzgerald, Eibhlin Conneally, Paul V Browne, Shaun R McCann, Mark P Lawler, Elisabeth Vandenberghe, Mark Lawler

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Chronic lymphocytic leukemia (CLL) follows a variable clinical course which is difficult to predict at diagnosis. We assessed somatic mutation (SHM) status, CD38 and ZAP-70 expression in 87 patients (49 male, 38 female) with stage A CLL and known cytogenetic profile to compare their role in predicting disease progression, which was assessed by the treatment free interval (TFI) from diagnosis. Sixty (69%) patients were SHM+, 24 (28%) were CD38+ and ten (12%) were ZAP-70+. The median TFI for: (i) SHM + versus SHM- patients was 124 versus 26 months; hazard ratio (HR) = 3.6 [95% confidence interval (CI) = 1.8 - 7.3; P = 0.001]: (ii) CD38- versus CD38+ patients was 120 versus 34 months; HR = 2.4 (95% CI = 1.4 - 5.3; P = 0.02); and (iii) ZAP70- versus ZAP70+ was 120 versus 16 months; HR = 3.4 (95% CI = 1.4 - 8.7; P = 0.01). SHM status and CD38 retained prognostic significance on multivariate analysis whereas ZAP-70 did not. We conclude that ZAP-70 analysis does not provide additional prognostic information in this group of patients.

Original languageEnglish
Pages (from-to)2371-9
Number of pages9
JournalLeukemia & lymphoma
Volume47
Issue number11
DOIs
Publication statusPublished - Nov 2006

Keywords

  • Adult
  • Aged
  • Aged, 80 and over
  • Antigens, CD38
  • Disease Progression
  • Female
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Immunoglobulin Heavy Chains
  • In Situ Hybridization, Fluorescence
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Male
  • Middle Aged
  • Mutation
  • Survival Rate
  • Tumor Markers, Biological
  • ZAP-70 Protein-Tyrosine Kinase

Fingerprint Dive into the research topics of 'CD38 expression level and pattern of expression remains a reliable and robust marker of progressive disease in chronic lymphocytic leukemia'. Together they form a unique fingerprint.

Cite this